Hemophagocytic Lymphohistiocytosis Active Not Recruiting Phase 1 / 2 Trials for Ruxolitinib (DB08877)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

Indication	Status	Phase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)	Active Not Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04551131	Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis	Treatment	Dexamethasone (DB01234) Etoposide (DB00773) Ruxolitinib (DB08877)